On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
Under the leadership of Pam Cheng, the company’s chief sustainability officer and EVP of Global Operations and IT, Breztri may soon be released in a new package with a new propellant that has 99.9% ...
(RTTNews) - AstraZeneca Plc.'s (AZN.L, AZN) triple-combination inhaler, Breztri Aerosphere, has shown positive results in late-stage clinical trials for patients with uncontrolled asthma. The trials, ...
Results showed budesonide/glycopyrronium/formoterol fumarate 320/28.8/9.6μg met all primary endpoints in both KALOS and LOGOS. Topline data were announced from two ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (AZN) will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American ...
Breztri can cost around $400 without insurance. Medicare drug plans may cover inhalers for COPD, including drugs like Breztri, but specific coverage and cost depend on the exact plan. Breztri ...
Vandana Singh May 2, 2025 at 9:18 AM 0 AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback